23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

Approach Summary Licensing status Publication and contact information Computational models Computational algorithm for designing G protein-coupled receptor (GPCR) ligands against a predefined set of targets A computational algorithm could be used to design GPCR ligands...
07:00 , Aug 22, 2011 |  BioCentury  |  Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Acadia Pharmaceuticals Inc, Allergan deal

Acadia and Allergan extended by one year through March 2012 a previously extended 2003 deal to discover and develop therapeutics based on Acadia's G protein-coupled receptor (GPCR) targets to treat glaucoma and other ophthalmic indications....
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Omeros deal

Omeros received $20 million from private investment firm Vulcan Capital and a $5 million grant from Washington State's Life Sciences Discovery Fund to advance Omeros' preclinical G protein-coupled receptor (GPCR) discovery program. Vulcan Capital and...
07:00 , Nov 1, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Look for shares of Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) to move on Monday after FDA approved an NDA late Friday for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Avanir said Nuedexta is the only...
00:38 , Oct 26, 2010 |  BC Extra  |  Financial News

Omeros lands $25M for GPCR program

Omeros Corp. (NASDAQ:OMER) received $20 million from Vulcan Capital and a $5 million grant from Washington State's Life Sciences Discovery Fund to advance Omeros' preclinical G protein-coupled receptor (GPCR) discovery program. Vulcan Capital and the...
23:32 , Aug 20, 2010 |  BC Extra  |  Financial News

Anchor raises $10 million

Anchor Therapeutics Inc. (Cambridge, Mass.) raised $10 million in a first close of a planned $15-$20 million series B round co-led by existing investors TVM Capital; HealthCare Ventures; and Novartis Option Fund. Anchor (formerly Ascent...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

7TM, J&J deal

7TM received an undisclosed milestone payment from Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary under a 2005 discovery deal. The milestone was triggered by the selection of an undisclosed clinical candidate. This is the second...